144 related articles for article (PubMed ID: 14756144)
21. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
22. Oxaliplatin. A platinum compound for colorectal cancer?
Balzer KM
Cancer Pract; 2000; 8(4):201-3. PubMed ID: 11898261
[No Abstract] [Full Text] [Related]
23. [Oxaliplatin -- A 10-Year Trajectory].
Kanaji S; Oki E; Saeki H; Kitao H; Maehara Y; Kakeji Y
Gan To Kagaku Ryoho; 2016 Jun; 43(6):715-22. PubMed ID: 27306807
[TBL] [Abstract][Full Text] [Related]
24. [Application of eloxatin for the treatment of widespread colorectal cancer].
Miasoiedov DV; Ievtushenko OI; Iugrinov OH
Klin Khir; 2001 Dec; (12):41-3. PubMed ID: 11944274
[No Abstract] [Full Text] [Related]
25. [Mechanism of action and pharmacology of new organometallic compounds active in the treatment of colorectal neoplasms].
Marchetti P; Gallà DA; Cifone G; Ricevuto E; Ficorella C
Tumori; 2000; 86(3 Suppl):S6-8. PubMed ID: 10969607
[No Abstract] [Full Text] [Related]
26. Colorectal cancer market.
Smith RE; Renaud RC; Hoffman E
Nat Rev Drug Discov; 2004 Jun; 3(6):471-2. PubMed ID: 15214331
[No Abstract] [Full Text] [Related]
27. [New insights into the combinability of Eloxation (oxaliplatin): present and future prospects].
Longo F
Tumori; 2003; 89(1):A1-2. PubMed ID: 12729376
[No Abstract] [Full Text] [Related]
28. [Development of L-OHP (trade name; Elplat)].
Terada K
Gan To Kagaku Ryoho; 2005 Aug; 32(8):1203-8. PubMed ID: 16121930
[TBL] [Abstract][Full Text] [Related]
29. From the Food and Drug Administration.
Crawford LM
JAMA; 2002 Sep; 288(10):1225. PubMed ID: 12215114
[No Abstract] [Full Text] [Related]
30. Oxaliplatin: a review of evolving concepts.
Mani S; Graham MA; Bregman DB; Ivy P; Chaney SG
Cancer Invest; 2002; 20(2):246-63. PubMed ID: 11901545
[No Abstract] [Full Text] [Related]
31. Eloxatin (Oxaliplatin) for Cancer Therapy 2002. Abstracts.
Onkologie; 2002 Aug; 25 Suppl 3():1-42. PubMed ID: 12389591
[No Abstract] [Full Text] [Related]
32. [Oxaliplatin (Eloxatin). Progress in cancer therapy].
Onkologie; 2001 Aug; 24 Suppl 4():1-41. PubMed ID: 11592268
[No Abstract] [Full Text] [Related]
33. Kidney cancer: Open gates for oxaliplatin.
Thoma C
Nat Rev Urol; 2016 Sep; 13(9):494. PubMed ID: 27502549
[No Abstract] [Full Text] [Related]
34. Is the NICE process flawed?
Cassidy J; Bridgewater J; Mainwaring P; Steward W; Wasan H
Lancet; 2002 Jun; 359(9323):2119-20. PubMed ID: 12086799
[No Abstract] [Full Text] [Related]
35. Platinum antitumour agents.
Dabrowiak JC; Bradner WT
Prog Med Chem; 1987; 24():129-58. PubMed ID: 3332917
[No Abstract] [Full Text] [Related]
36. Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? National Institute of Clinical Excellence.
Saunders MP; Valle JW
Br J Cancer; 2002 Jun; 86(11):1667-9. PubMed ID: 12087447
[No Abstract] [Full Text] [Related]
37. Marketing medicines through randomised controlled trials: the case of interferon.
Pieters T
BMJ; 1998 Oct; 317(7167):1231-3. PubMed ID: 9794868
[No Abstract] [Full Text] [Related]
38. The colorectal cancer drug market.
Ramos García L; Webster RM
Nat Rev Drug Discov; 2024 Jun; 23(6):414-415. PubMed ID: 38336887
[No Abstract] [Full Text] [Related]
39. [Importance of Post-Marketing Studies in Gathering of Clinical Evidences for Proper Usage of Anti-Cancer Drugs, and the StudyRequirements for Their Credibility].
Inagaki O
Gan To Kagaku Ryoho; 2016 Apr; 43(4):480-2. PubMed ID: 27220799
[TBL] [Abstract][Full Text] [Related]
40. The Use of Superlatives in Cancer Research.
Abola MV; Prasad V
JAMA Oncol; 2016 Jan; 2(1):139-41. PubMed ID: 26512913
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
